Tisotumab vedotin by Genmab for Metastatic Colorectal Cancer: Likelihood of Approval
Tisotumab vedotin is under clinical development by Genmab and currently in Phase II for Metastatic Colorectal Cancer.
Source: pharmaceutical-technology.com
Page 2 - Pharmaceutical Intelligence News Today : Breaking News, Live Updates & Top Stories | Vimarsana
Stay updated with breaking news from Pharmaceutical Intelligence. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Top News In Pharmaceutical Intelligence Today - Breaking & Trending Today
Tisotumab vedotin by Genmab for Bladder Cancer: Likelihood of Approval
Tisotumab vedotin is under clinical development by Genmab and currently in Phase II for Bladder Cancer.
Source: pharmaceutical-technology.com
Sirexatamab by Leap Therapeutics for Endometrial Cancer: Likelihood of Approval
Sirexatamab is under clinical development by Leap Therapeutics and currently in Phase II for Endometrial Cancer.
Source: pharmaceutical-technology.com
Sirexatamab by Leap Therapeutics for Hepatocellular Carcinoma: Likelihood of Approval
Sirexatamab is under clinical development by Leap Therapeutics and currently in Phase II for Hepatocellular Carcinoma.
Source: pharmaceutical-technology.com
Entrectinib by F. Hoffmann-La Roche for Metastatic Uveal Melanoma: Likelihood of Approval
Entrectinib is under clinical development by F. Hoffmann-La Roche and currently in Phase II for Metastatic Uveal Melanoma.
Source: pharmaceutical-technology.com